Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") announces that a digital Q&A session with Klaria's CEO Scott Boyer and chairman Fredrik Hübinette has been published.
The Q&A session covers topics including the licensing partner CNX Therapeutics ("CNX") upcoming launch of Sumatriptan Alginate Film in Europe, the Company's potential to sign similar commercial agreements for other markets including the US, Klaria's other pipeline projects and the ongoing rights issue.
The Q&A session is available on Klaria's issue page: https://www.ii.se/klaria-rights-issue-of-units-2026/#video
Klaria Pharma is currently carrying out a rights issue with a subscription period from 14 October 2026 up to and including 6 November 2026. The proceeds will significantly strengthen the Company's balance sheet and thereby create room for manoeuvre, improved negotiating position vis-à-vis potential partners and thereby good conditions to maximize value for Klaria's shareholders.